相关实验视频

Updated: Sep 19, 2025

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Published on: December 17, 2019

放射性免疫疗法作为治疗CD30阳性淋巴瘤的方法

Elisa Rioja-Blanco^1,2, Yara Banz³, Christoph Schlapbach⁴

¹Center for Radiopharmaceutical Sciences, PSI Center for Life Sciences, Villigen-PSI, Switzerland.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine

|June 2, 2025

概括

使用卢铁-177 (177Lu) 和-161 (161Tb) 的新型放射性免疫疗法在治疗CD30阳性淋巴瘤方面表现有前途. 161Tb在临床前模型中表现出优异的疗效和延长的存活期,突出了其在向癌症治疗中的潜力.

科学领域:

核医学就是核医学.
在瘤学瘤学.
放射化学放射化学是指辐射化学.

背景情况:

淋巴瘤治疗需要创新的策略,因为它对健康的影响很大.
-161 (161Tb) 具有独特的放射性特性,包括Auger和转换电子共发射,可能增强细胞杀死功效.
CD30是一种经常在各种淋巴瘤中过度表达的受体,使其成为一个可行的治疗点.

研究的目的:

为了比较161Tb标记的放射性免疫治疗与177Lu标记的治疗对CD30阳性淋巴瘤的疗效.
评估161Tb独特的电子排放对治疗结果的影响.
通过使用光蛋白组学来研究治疗效果的基础分子机制.

主要方法:

在体外评估细胞活力,存活率和DNA损伤,在CD30阳性T细胞淋巴瘤细胞系中使用161Tb和177Lu标记的抗CD30抗体 (cAC10).
在异种移植小鼠模型中进行体内研究,以确定生物分布,剂量测量和治疗效果.
定量蛋白质组学和蛋白质组学分析,其次是生物信息学,以探索治疗诱导的分子变化.

主要成果:

161Tb-cAC10在体外表现出优异的CD30特异性细胞毒性.
在体内研究显示了有利的生物分布和更高的瘤吸收剂量为161Tb.
与177Lu-cAC10相比,单剂量161Tb-cAC10显著延长了小鼠的存活时间 (中位数为41天而不是21天).
蛋白组分析表明,161Tb诱导的DNA损伤反应和细胞循环途径的更明显的改变比177Lu.

结论:

161Tb放射性免疫疗法是对CD30阳性T细胞淋巴瘤的高度有效治疗方法.
这项研究代表了161Tb对血液瘤的首次评估.
在活体中,蛋白组学提供了关于161Tb在放射性免疫治疗中比177Lu更高效的宝贵见解.

关键词:

161Tbb,这是一个巨大的数字.CD3030 是一个CD3030 是一个CD30.淋巴瘤淋巴瘤是什么素蛋白质组学素蛋白质组学素蛋白质组学放射性免疫疗法是一种放射性免疫疗法.

更多相关视频

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Published on: January 29, 2019

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Published on: May 24, 2024

相关概念视频

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...